




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 501/18, 501/04, A61K 31/545		A1	(11) International Publication Number: WO 97/24358
(21) International Application Number: PCT/KR96/00250		(43) International Publication Date: 10 July 1997 (10.07.97)	
(22) International Filing Date: 26 December 1996 (26.12.96)		(81) Designated States: JP, US, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(30) Priority Data: 1995/58694 27 December 1995 (27.12.95) KR 1995/58695 27 December 1995 (27.12.95) KR		Published <i>With international search report.</i>	
(71) Applicant (for all designated States except US): HANMI PHARMACEUTICAL CO., LTD. [KR/KR]; 893-5, Haju-ri, Paltan-myun, Hwasung-gun, Kyunggi-do 445-910 (KR).			
(72) Inventors; and			
(75) Inventors/Applicants (for US only): LEE, Gwan, Sun [KR/KR]; Geukdong Apartment #2-806, Karak-dong, Songpa-gu, Seoul 138-160 (KR). CHANG, Young, Kil [KR/KR]; 34-4, Samjeon-dong, Songpa-gu, Seoul 138-180 (KR). CHUN, Jong, Pil [KR/KR]; 96-28, Mok-dong, Chung-gu, Daejeon 301-070 (KR). KOH, Joon, Hyung [KR/KR]; Jugong Apartment #1004-401, Chungang-dong, Kwacheon-shi, Kyunggi-do 427-010 (KR).			
(74) Agents: CHOI, Kyu, Pal et al.; 824-20, Yeoksam-dong, Kangnam-ku, Seoul 135-080 (KR).			

(54) Title: PROCESS FOR PREPARATION OF CEFIDINIR



(57) Abstract

The present invention relates to a novel crystalline cefdinir intermediate having formula (II) which can be used very usefully for preparing a cephalosporin antibiotics, cefdinir, in which Ph represents phenyl, p-TsOH represents p-toluenesulfonic acid, and DMAC represents N,N-dimethylacetamide, to a process for preparation thereof and to a process for preparing cefdinir using the compound of formula (II). According to the present invention, cefdinir can be prepared in an excellent color and purity and with a good yield.

FOR THE PURPOSES OF INFORMATION ONLY


Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

PROCESS FOR PREPARATION OF CEF DINIR
TECHNICAL FIELD

The present invention relates to a process for preparing cefdinir
5 represented by the following formula (I) as a cephalosporin antibiotics :

10



BACKGROUND ART


15 Cefdinir of formula (I) above has a chemical name of 7β -[2-(2-aminothiazol-4-yl)-2-(Z)-(hydroxyimino)acetamido]-3-vinyl-3-cep-
-hem-4-carboxylic acid. It is the third generation of cephalosporin
antibiotics for oral administration and has a broader antibacterial
spectrum over the general gram positive and gram negative bacteria than
20 other antibiotics for oral administration. Particularly, it has been
reported that cefdinir has an excellent antibacterial activity against
Staphylococci and Streptococci.

30 In US Patent No. 4,559,334 is disclosed a process for preparing
25 cefdinir as represented in the following reaction scheme 1.

35

35

Reaction Scheme 1 :



25 In the above reaction, 7-amino-3-vinyl-3-cephem-4-carboxylic acid ester(A) is reacted with a reactive carboxylic acid derivative to obtain an 7-amido compound(B), and this compound is treated with a nitrosating agent to prepare an N-oxime compound(C). Continually, the compound(C) is cyclized with thiourea to prepare an aminothiazole compound(D), and then finally cefdinir of formula (I) is prepared by removing the carboxy protecting group.


30 35 In case cefdinir is prepared according to the reaction scheme 1, however, there can occur many problems such that the process for preparing the 7-amido compound(B) should be carried out at a

temperature below -20°C under an anhydrous condition and that the isolation of the N-oxime compound(C) may cause a lot of troubles in the procedure of industrialization since the compound(C) is obtained as a solid having a syrup or a foam phase after the solvent is distilled off under reduced pressure. In addition, the aminothiazole compound(D) is obtained in a poor yield and purity and with a brownish poor color, which finally exerts a harmful influence upon the purity and color of the desired cefdinir. Further, in the reaction scheme 1, since cefdinir is synthesized through a complicated reaction consisting of 4 steps from the expensive 7-amino-3-vinyl-3-cephem-4-carboxylic acid derivative, the cost for production of cefdinir increases according as the whole reaction yield decreases.

DISCLOSURE OF INVENTION

15

Thus, the present inventors have extensively studied to develop a novel process by which cefdinir can conveniently be prepared in a good yield and a high purity. As a result, we have identified that such a purpose can be achieved by using a novel cefdinir intermediate represented by the following formula (II) as a starting substance and then completed the present invention.



in which

30 Ph represents phenyl,
 p-TsOH represents p-toluenesulfonic acid, and
 DMAC represents N,N-dimethylacetamide.

Thus, it is an object of the present invention to provide a novel 35 process for preparing cefdinir using the intermediate of formula (II) as a

starting substance.

It is another object of the present invention to provide a novel intermediate of formula (II), as defined above, and process for preparation
5 thereof.

BRIEF DESCRIPTION OF DRAWINGS

For a thorough understanding of the nature and objects of the
10 invention, reference should be made to the following detailed description
taken in connection with the accompanying drawings in which :

Figure 1 represents a X-ray powder diffraction spectrum of the
compound of formula (II) ;

15 Figure 2 represents an IR spectrum of the compound of formula
(II) ; and

Figure 3 represents a NMR spectrum of the compound of formula
20 (II).


BEST MODE FOR CARRYING OUT THE INVENTION

In one aspect, the present invention pertains to a process for
25 preparing cefdinir of formula (I) characterized in that a trityl protecting
group in the cefdinir intermediate of formula (II) is removed in the
presence of an acid. The process is depicted in the following reaction
scheme 2.

30

35

Reaction Scheme 2 :



The most important feature in the process for preparing cefdinir according to the present invention is that the novel cefdinir intermediate of formula (II) which is very excellent in yield and purity is used as a starting material.

As the acid which can be used in the process for preparing cefdinir according to the present invention, an inorganic acid such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, Lewis acid, etc.; an organic acid such as acetic acid, formic acid, trifluoroacetic acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, etc.; or an acidic hydrogen ion exchange resin can be mentioned, wherein Lewis acid includes boron trifluoride, boron trifluoride ethyletherate, aluminum chloride, antimony pentachloride, ferrous chloride, stannous chloride, titanium tetrachloride, zinc chloride, etc. When an organic acid such as trifluoroacetic acid or p-toluenesulfonic acid, or a Lewis acid is selected, it is preferable that the reaction is carried out in the presence of an anisole as a cation capturing agent. The acid is preferably used in an amount of 1 to 20 equivalents with respect to the starting material.

(II).

It is preferable to carry out the reaction at a low temperature in a range of -30 to 5°C. But, the reaction can also be performed at 40 to 5 70°C in case of using the acid in an amount of 1 to 2 equivalents with respect to the cefdinir intermediate of formula (II).

As the solvent, one or more selected from a group consisting of water, ethanol, methanol, propanol, t-butanol, tetrahydrofuran, dioxane, 10 N,N-dimethylformamide, N,N-dimethylacetamide, methylene chloride and chloroform can be used, and if desired, the organic acid or inorganic acid itself can be used as a reaction solvent.

The cefdinir of formula (I) prepared according to the process as 15 explained above exhibits a superior quality in color, yield and purity to that prepared according to the earlier process, and such a result is basically caused by use of the cefdinir intermediate of formula (II) as a starting material. That is, this intermediate is a crystalline compound having a pale yellow color and a high purity more than 98%, therefore 20 it's good quality has a beneficial effect on the next step for finally producing cefdinir having an excellent quality.

Generally, the earlier process for preparing cefdinir from the reactive derivative has problems that 1-hydroxybenzotriazole or 25 2-mercaptobenzothiazole produced during the reaction can hardly be removed from the reaction mixture, which lowers the purity of the reaction product and also makes the purifying step difficult. Upon considering this, the present invention having no such problems can be estimated as an astounding one.

30

Furthermore, in the prior art, cefdinir can be prepared from the expensive compound(A) through a 4-step reaction. In contrast, in the present invention, only 2 steps of reaction are needed for the preparation of the final product, cefdinir. Therefore, a lot of beneficial effects can 35 be expected by applying the present invention for preparing cefdinir such


that a decrease of the yield due to the multi-step reaction can be prevented; the product can be provided with a low price since there is no need to use the expensive material; and the manufacturing time can be saved by cutting the reaction steps in half, and the like.


5

In another aspect, the present invention pertains to the compound of formula (II) above and process for preparing the same.


The cefdinir intermediate of formula (II) used as a starting material in the reaction scheme 2 is a crystalline complex with a salt and a solvent, and it can easily be prepared by reacting a reactive ester having the following formula (III) with a 3-cephem derivative having the following formula (IV) in a solvent in the presence or absence of a base and then by adding p-toluenesulfonic acid thereto. The reaction is depicted in the following reaction scheme 3 :

Reaction Scheme 3 :





5



wherein R' represents C₁-C₄ alkyl or phenyl, or R' together with phosphorus and oxygen atoms to which R' is attached can form a 5 to 6-membered heterocycle.

The reactive ester compound of formula (III) used as a starting substance in the reaction scheme 3 above is a known compound and can be prepared according to the process disclosed in literatures (see, 15 European Patent Laid-open Publication No. 555,769; Japanese Patent Laid-open Publication No. sho 57-175,196). The 3-cephem derivative of formula (IV) can also be prepared easily according to the known method described in US Patent No. 4,423,213.

20 The reactive ester compound of formula (III) is used in an amount of 0.8 to 2.0 equivalents, preferably 1.0 to 1.2 equivalents with respect to the 3-cephem derivative of formula (IV). The solvent which can be used in the reaction of scheme 3 includes, N,N-dimethylacetamide alone, or a mixture of N,N-dimethylacetamide with one or more selected from a 25 group consisting of ethanol, methanol, isopropanol, diethylether, tetrahydrofuran, dioxane, methylene chloride, chloroform, acetonitrile, ethyl acetate and acetone. In this case, the solvent is used in an amount of 10 to 60ml, preferably 10 to 30ml with respect to 1g of the 3-cephem derivative of formula (IV).

30

Generally, the reaction is carried out at a temperature of -15 to 40 °C, preferably 0 to 30°C. The reaction is completed after 1 to 24 hours have passed from the initial point, however, it is desirable to complete the reaction within 1 to 5 hours since the color of the reaction solution 35 becomes poor and the amount of side products increases as the reaction

time becomes longer.

The process for preparing the compound (II) of the present invention can be carried out in the presence of a base. If a base is used, tertiary amines such as triethylamine, tri-n-butylamine, diisopropylethylamine, triethylenediamine, pyridine, N,N-dimethylaniline, etc., preferably triethylamine or tri-n-butylamine can be used as the base. The base can be used in an amount of 0.5 to 5 equivalents, preferably 1 to 2 equivalents with respect to the 3-cephem derivative of formula (IV). On the other hand, the reaction can also be carried out by using N-trimethylsilylacetamide or N,O-bistrimethylsilylacetamide in an amount of 1 to 3 equivalents with respect to the 3-cephem derivative of formula (IV) instead of the base.

After the reaction is completed under the conditions as explained above, diethylether, diisopropylether or ethylacetate is added to the reaction mixture to crystallize the product in the work-up procedure. In this case, they are added in an amount of 2 to 6 times by volume with respect to the reaction solvent, however, it is desirable to add them in an amount of 3 to 5 times by volume considering the reaction yield and purity.

On the other hand, p-toluenesulfonic acid is usually used in an amount of 1 to 4 equivalents, preferably 2 to 3 equivalents with respect to the 3-cephem derivative of formula (IV).

The cefdinir intermediate of formula (II) thus produced is a crystalline complex with a salt and a solvent, and it has a unique structure wherein one molecule of p-toluenesulfonic acid and two molecules of N,N-dimethylacetamide are attached to the main structure. Accordingly, it can be isolated more easily from the reaction mixture in a high purity than the usual cephalosporin compound having a noncrystalline form.

It is recognized through a X-ray powder diffraction analysis that

the compound (II) has a different crystalline form from other noncrystalline compounds. Particularly, in the X-ray powder diffraction spectrum of Figure 1, the characteristic peak of the compound (II) is well represented. The unique Debye-Scherrer X-ray powder diffraction pattern of the crystalline compound of formula (II) is described in the 5 following Table 1.

In Table 1 below, " θ " represents a diffraction angle, "d" represents a spacing between the layers, and " I/I_0 " represents a relative 10 intensity.

15

20

25

30

35

Table 1. Debye-Scherrer X-ray powder diffraction pattern of the compound of formula (II)

	θ	d	I / Io	θ	d	I / Io
5	4.28	20.63	18	19.64	4.52	19
	8.06	10.96	29	20.32	4.37	20
	8.36	10.57	38	20.62	4.31	51
	8.88	9.95	22	20.82	4.26	28
10	9.14	9.67	18	21.06	4.21	46
	10.08	8.77	15	21.58	4.11	34
	11.22	7.88	34	21.76	4.08	23
	11.44	7.73	28	22.24	3.99	20
15	12.02	7.36	33	22.58	3.93	18
	12.92	6.85	20	23.02	3.86	25
	13.28	6.66	32	23.34	3.81	17
	15.24	5.81	18	23.48	3.79	21
20	15.56	5.69	27	24.24	3.67	39
	16.20	5.47	22	25.04	3.55	21
	16.76	5.29	19	25.12	3.54	16
	17.14	5.17	95	25.70	3.46	29
25	17.24	5.14	81	26.04	3.42	19
	17.62	5.03	29	26.62	3.35	16
	18.14	4.89	69	27.22	3.27	17
	18.50	4.79	87	27.76	3.21	16
30	18.54	4.78	100	29.28	3.05	18
	18.76	4.73	60	29.48	3.03	20

In addition, the structure of the intermediate (II) is identified qualitatively through IR and NMR spectroscopy (see, Figure 1 to 3)

Hereinafter, the present invention will be more specifically explained by the following examples. However, it should be understood that the following examples are intended to illustrate the present invention and not to limit the scope of the present invention in any manner.

EXAMPLE 1: Synthesis of 7β-[2-(2-aminothiazol-4-yl)-2(Z)-(trityloxyimino)acetamido]-3-vinyl-3-cephem-4-carboxylic acid · p-toluene sulfonic acid · 2 N,N-dimethylacetamide

8.0g (35.4mmol) of 7-amino-3-vinyl-3-cephem-4-carboxylic acid and 21.5g (37.1mmol) of (Z)-(2-aminothiazol-4-yl)-2-trityloxyiminoacetic acid 2-benzothiazolyl thioester were suspended in 80ml of N,N-dimethylacetamide and 16.8ml (70.0mmol) of tri-n-butylamine was added thereto. Then, the reaction mixture was stirred for 1 hour while keeping the temperature at 15 to 20°C and 240ml of diethylether was added to the mixture. The reaction mixture thus prepared was stirred for 30 minutes and then filtered through a cellite. To the filtrate was added 20.2g (0.11mol) of p-toluenesulfonic acid · monohydrate dissolved in 40ml of methanol and the resulting solution was stirred for 2 hours at room temperature. After 160ml of diethylether was further added thereto, the whole solution was stirred for one hour at room temperature, cooled to 0 to 5°C, stirred for one hour and filtered. The crystal thus obtained was washed sequentially with 50ml of N,N-dimethylacetamide-diethylether(1:5, v/v) and 50ml of diethylether and then dried to obtain 32.3g (Yield 93%) of the title compound as a pale yellow crystal.

- HPLC Purity : 99.2%
- m.p.(°C) : 164 - 165
- IR(KBr, cm⁻¹) : 3061, 1780, 1622, 1192
- ¹H-NMR(MeOH-d₄) δ : 2.0(s,6H), 2.3(s,3H), 2.9(s,6H), 3.0(s,6H), 3.7(s,2H), 5.0-6.0(m,4H), 6.9-7.5(m,17H), 7.7(d,2H,J=8Hz)

EXAMPLE 2

10.0g (44.0mmol) of 7-amino-3-vinyl-3-cephem-4-carboxylic acid and 27.0g (46.4mmol) of (Z)-(2-aminothiazol-4-yl)-2-trityloxyiminoacetic acid 2-benzothiazolylthioester were mixed in 200ml of N,N-dimethylacetamide. 22.0ml (89.0mmol) of N,O-bistrimethylsilylacetamide was added thereto and then the resulting mixture was stirred overnight at 10 to 20°C. After 600ml of diethylether and 10ml of methanol were added to the mixture, the whole mixture was stirred for 30 minutes and then 10 filtered through a cellite. To the filtrate was added 12.6g (66.2mmol) of p-toluenesulfonic acid · monohydrate dissolved in 40ml of methanol and the resulting solution was stirred for 3 hours. After 400ml of diethylether was further added thereto, the solution was stirred for 2 hours and then filtered. The crystal thus obtained was washed sequentially with 60ml of N,N-dimethylacetamide-diethylether(1:5, v/v) and 100ml of diethylether and then dried to obtain 38.3g (Yield 88%) of 7-β-[2-(2-aminothiazol-4-yl)-2(Z)-(trityloxyimino)acetamido]-3-vinyl-3-cephem-4-carboxylic acid · p-toluenesulfonic acid · 2 N,N-dimethylacetamide as a pale yellow crystal. The purity of the product determined by 20 HPLC analysis was 99.4%, and melting point, IR and ¹H-NMR data were identical to those described in Example 1.

EXAMPLE 3

25 18.9g (32.5mmol) of diethylthiophosphoryl (Z)-(2-aminothiazol-4-yl)-2-trityloxyiminoacetate was dissolved in 105ml of N,N-dimethylacetamide. 7.0g (31mmol) of 7-amino-3-vinyl-3-cephem-4-carboxylic acid and 8.6ml (62mmol) of triethylamine were added thereto and then the resulting mixture was stirred for 2 hours at room temperature. 210ml of 30 diethylether was added to the mixture, which was then stirred for 30 minutes and filtered through a cellite. To the filtrate was added 17.7g (93mmol) of p-toluenesulfonic acid · monohydrate dissolved in 25ml of ethanol and the resulting solution was stirred for one hour and a half. After 210ml of diethylether was further added thereto, the solution was 35 filtered to obtain a crystal. The crystal thus obtained was washed

sequentially with 50ml of N,N-dimethylacetamide-diethylether(1:5, v/v) and 50ml of diethylether and then dried to obtain 26.2g (Yield 86%) of 7 β -[2-(2-aminothiazol-4-yl)-2(Z)-(trityloxyimino)acetamido]-3-vinyl-3-cephem-4-carboxylic acid · p-toluenesulfonic acid · 2 N,N-dimethylacetamide as a pale yellow crystal. The purity of the product determined by HPLC analysis was 98.5%, and melting point, IR and 1 H-NMR data were identical to those described in Example 1.

EXAMPLE 4

10 10.0g (44.0mmol) of 7-amino-3-vinyl-3-cephem-4-carboxylic acid and 27.0g (46.4mmol) of (Z)-(2-aminothiazol-4-yl)-2-trityloxyiminoacetic acid 2-benzothiazolylthioester were suspended in 150ml of N,N-dimethylacetamide. 21.0ml (88.0mmol) of tri-n-butylamine was
15 added thereto and the mixture was stirred for 1 hour and a half at 15 to 25°C. 25.2g (133mmol) of p-toluenesulfonic acid · monohydrate was added to the mixture and thoroughly dissolved, 450ml of diisopropylether was added thereto and then the whole mixture was stirred for 2 hours. After 300ml of diisopropylether was added to the mixture, the resulting
20 solution was stirred for 2 hours, cooled to about 5°C, stirred for 1 hour and filtered to obtain a crystal. The crystal thus obtained was washed sequentially with 50ml of N,N-dimethylacetamide-diethylether(1:5, v/v) and 50ml of diethylether and then dried to obtain 41.8g (Yield 96%) of 7 β -[2-(2-aminothiazol-4-yl)-2(Z)-(trityloxyimino)acetamido]-3-vinyl-3-cephem-4-carboxylic acid · p-toluenesulfonic acid · 2 N,N-dimethylacetamide as a pale yellow crystal. The purity of the product determined by HPLC analysis was 98.2%, and melting point, IR and 1 H-NMR data were identical to those described in Example 1.

30 EXAMPLE 5

10.0g (44.0mmol) of 7-amino-3-vinyl-3-cephem-4-carboxylic acid and 30.8g (53mmol) of (Z)-(2-aminothiazol-4-yl)-2-trityloxyiminoacetic acid 2-benzothiazolylthioester were mixed in 200ml of N,N-dimethylacetamide. 21.1ml (88mmol) of tri-n-butylamine was added thereto and

then the resulting mixture was stirred overnight at room temperature. After 400ml of diethylether and 2g of activated charcoal were added to the mixture, the whole mixture was stirred for 1 hour and then filtered through a cellite. To the filtrate was added 16.8g (88mmol) of 5 p-toluenesulfonic acid · monohydrate dissolved in 30ml of methanol and the resulting solution was stirred for 2 hours. After 400ml of diethylether was further added thereto, the solution was stirred for 2 hours and then filtered. The crystal thus obtained was washed sequentially with 50ml of N,N-dimethylacetamide-diethylether(1:5, v/v) 10 and 50ml of diethylether and then dried to obtain 37.0g (Yield 85%) of 7 β -[2-(2-aminothiazol-4-yl)-2(Z)-(trityloxyimino)acetamido]-3-vinyl-3-cephem-4-carboxylic acid · p-toluenesulfonic acid · 2 N,N-dimethylacetamide as a pale yellow crystal. The purity of the product determined by 15 HPLC analysis was 98.5%, and melting point, IR and 1 H-NMR data were identical to those described in Example 1.

EXAMPLE 6: Synthesis of 7 β -[2-(2-aminothiazol-4-yl)-2(Z)-(hydroxyimino)acetamido]-3-vinyl-3-cephem-4-carboxylic acid

20 15.0g (15.2mmol) of 7 β -[2-(2-aminothiazol-4-yl)-2(Z)-(trityloxyimino)acetamido]-3-vinyl-3-cephem-4-carboxylic acid · p-toluenesulfonic acid · 2 N,N-dimethylacetamide was dissolved in 90ml of methanol and then 0.51ml (15.2mmol) of 99% formic acid was added thereto. After the resulting mixture was stirred for 5 hours under reflux, the methanol 25 contained therein was removed under reduced pressure and 50ml of water, 30ml of tetrahydrofuran and 60ml of ethylacetate were added to the residue. The pH of the solution was adjusted to 6.5 to 7.5 by adding sodium hydrogen carbonate little by little. The aqueous layer was separated, washed with a solvent mixture of 30ml of tetrahydrofuran and 30ml of ethylacetate, and then adjusted to pH 2.4 to 2.8 using 2N-HCl. The crystal thus precipitated was stirred for 1 hour under ice-bath, 35 filtered, washed with 30ml of water and dried to obtain 5.5g (Yield 92%) of the title compound as a pale yellow solid.

35 • HPLC Purity : 99.2%

- IR(KBr, cm^{-1}) : 3300, 1780, 1665, 1180, 1130
- $^1\text{H-NMR}(\text{DMSO}-\text{d}_6)$ δ : 3.5, 3.80(2H,ABq,J=18Hz), 5.2(1H,d,J=5Hz), 5.3(1H,d,J=10Hz), 5.6(1H,d,J=17Hz), 5.8(1H,dd,J=8Hz,5Hz), 6.7(1H,s), 6.9(1H,dd,J=17Hz,10Hz), 7.1(2H,brs), 9.4(1H,d,J=8Hz), 11.3(1H,brs)

5

EXAMPLE 7

10.0g (10.2mmol) of 7β -[2-(2-aminothiazol-4-yl)-2(Z)-(trityloxy-imino)acetamido]-3-vinyl-3-cephem-4-carboxylic acid · p-toluenesulfonic acid · 2 N,N-dimethylacetamide was dissolved in 20ml of methanol and then 20ml (0.26mol) of trifluoroacetic acid and 10ml (92mmol) of anisole were added thereto. After the mixture was stirred for 5 hours at 40 to 45°C, the methanol contained therein was removed under reduced pressure. The residue was dispersed in 200ml of ethylacetate, and then the resulting solution was stirred for 30 minutes and filtered. The pale yellow solid thus obtained was dried and dissolved in 60ml of water, 30ml of tetrahydrofuran and 60ml of ethylacetate. The pH of the solution was adjusted to 5.5 to 6.5 by adding sodium hydrogen carbonate little by little. The aqueous layer was separated, washed with a solvent mixture of 30ml of tetrahydrofuran and 60ml of ethylacetate, and then adjusted to pH 2.4 to 2.8 using 2N-HCl. The crystal thus precipitated was stirred for 1 hour under ice-bath, filtered, washed with 30ml of water and dried to obtain 3.6g (Yield 90%) of 7β -[2-(2-aminothiazol-4-yl)-2(Z)-(hydroxyimino)acetamido]-3-vinyl-3-cephem-4-carboxylic acid as a pale yellow solid. The purity of the product determined by HPLC analysis was 99.4%, and IR and $^1\text{H-NMR}$ data were identical to those described in Example 6.

30

EXAMPLE 8

To 5.0g (5.1mmol) of 7β -[2-(2-aminothiazol-4-yl)-2(Z)-(trityloxy-imino)acetamido]-3-vinyl-3-cephem-4-carboxylic acid · p-toluenesulfonic acid · 2 N,N-dimethylacetamide was added 15ml of 85% formic acid and the mixture was stirred for 2 hours at room temperature. After

tritylcarbinol thus precipitated was removed by filtration, the filtrate was concentrated under reduced pressure. To the residue were added 30ml of water, 10ml of tetrahydrofuran and 20ml of ethylacetate. The pH of the solution was adjusted to 6.5 by adding sodium hydrogen carbonate little by little. The aqueous layer was separated, washed with a solvent mixture of 10ml of tetrahydrofuran and 20ml of ethylacetate, and then adjusted to pH 2.4 to 2.8 using 2N-HCl. The crystal thus precipitated was stirred for 1 hour under ice-bath, filtered, washed with 10ml of water and dried to obtain 1.9g (Yield 93%) of 7β -[2-(2-aminothiazol-4-yl)-2(Z)-(hydroxyimino)acetamido]-3-vinyl-3-cephem-4-carboxylic acid as a pale yellow solid. The purity of the product determined by HPLC analysis was 99.1%, and IR and $^1\text{H-NMR}$ data were identical to those described in Example 6.

15

20

25


30

35

WHAT IS CLAIMED IS :


1. A process for preparing cefdinir having the following formula (I),

5



10 characterized in that a trityl protecting group in a cefdinir intermediate having the following formula (II),

15



in which Ph represents phenyl, p-TsOH represents p-toluenesulfonic acid, and DMAC represents N,N-dimethylacetamide, is removed in the
20 presence of an acid.

2. The process according to claim 1, wherein the acid is an inorganic acid, an organic acid, or an acidic hydrogen ion exchange resin.

25 3. The process according to claim 2, wherein the inorganic acid is selected from a group consisting of hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid and Lewis acid.

30 4. The process according to claim 3, wherein the Lewis acid is selected from a group consisting of boron trifluoride, boron trifluoride ethyletherate, aluminum chloride, antimony pentachloride, ferrous chloride, stannous chloride, titanium tetrachloride and zinc chloride.

35 5. The process according to claim 2, wherein the organic acid is selected from a group consisting of acetic acid, formic acid, trifluoroacetic

acid, methanesulfonic acid, benzenesulfonic acid and *p*-toluenesulfonic acid.


6. The process according to claim 2, wherein the reaction is carried
5 out in the presence of a cation capturing agent when a Lewis acid or an
organic acid is used.

7. The process according to claim 6, wherein the cation capturing agent is anisole.

10

8. The process according to claim 1, wherein the acid is used in an amount of 1 to 20 equivalents with respect to the compound of formula (II).

15 9. A crystalline cesdinir intermediate having the following formula (II) :



in which

Ph represents phenyl,

p-TsOH represents p-toluenesulfonic acid, and

25 DMAc represents N,N-dimethylacetamide

10. The intermediate of formula (II) according to claim 9, wherein it shows the X-ray powder diffraction pattern of the following Table 1.

30


35

Table 1.

	θ	d	I / Io		θ	d	I / Io
5	4.28	20.63	18		19.64	4.52	19
	8.06	10.96	29		20.32	4.37	20
	8.36	10.57	38		20.62	4.31	51
	8.88	9.95	22		20.82	4.26	28
	9.14	9.67	18		21.06	4.21	46
10	10.08	8.77	15		21.58	4.11	34
	11.22	7.88	34		21.76	4.08	23
	11.44	7.73	28		22.24	3.99	20
	12.02	7.36	33		22.58	3.93	18
	12.92	6.85	20		23.02	3.86	25
15	13.28	6.66	32		23.34	3.81	17
	15.24	5.81	18		23.48	3.79	21
	15.56	5.69	27		24.24	3.67	39
	16.20	5.47	22		25.04	3.55	21
	16.76	5.29	19		25.12	3.54	16
20	17.14	5.17	95		25.70	3.46	29
	17.24	5.14	81		26.04	3.42	19
	17.62	5.03	29		26.62	3.35	16
	18.14	4.89	69		27.22	3.27	17
	18.50	4.79	87		27.76	3.21	16
25	18.54	4.78	100		29.28	3.05	18
	18.76	4.73	60		29.48	3.03	20


In Table 1 above, " θ " represents a diffraction angle, "d" represents a spacing between the layers, and "I/I_o" represents a relative intensity.

11. A process for preparing a compound having the following formula (II),




in which Ph represents phenyl, p-TsOH represents p-toluenesulfonic acid, and DMAC represents N,N-dimethylacetamide, characterized in that a reactive ester having the following formula (III),

10



15


in which Z represents



20

or $\text{--O--P}(\text{OR}')_2^S$, wherein R' represents C₁-C₄ alkyl or phenyl, or R' together with phosphorus and oxygen atoms to which R' is attached can 25 form a 5 to 6-membered heterocycle, is reacted with a 3-cephem derivative having the following formula (IV),

30



in a solvent in the presence or absence of a base, and then p-toluenesulfonic acid is added thereto.

35

12. The process according to claim 11, wherein the reactive ester of formula (III) is used in an amount of 0.8 to 2.0 equivalents with respect to the 3-cephem derivative of formula (IV).

5 13. The process according to claim 11, wherein the solvent is N,N-dimethylacetamide alone, or a mixture of N,N-dimethylacetamide with one or more selected from a group consisting of ethanol, methanol, isopropanol, diethylether, tetrahydrofuran, dioxane, methylene chloride, chloroform, acetonitrile, ethylacetate and acetone.

10 14. The process according to claim 11, wherein the reaction is carried out at a temperature of -15 to 40°C.

15 15. The process according to claim 11, wherein a tertiary amine is used as the base.

16. The process according to claim 15, wherein the tertiary amine is triethylamine or tri-n-butylamine.

20 17. The process according to claim 11, wherein N-trimethylsilylacetamide or N,O-bistrimethylsilylacetamide is used in the absence of a base.

25 18. The process according to claim 11, wherein p-toluenesulfonic acid is used in an amount of 1 to 3 equivalents with respect to the 3-cephem derivative of formula (IV).

30 19. The process according to claim 11, wherein one selected from a group consisting of diethylether, diisopropylether and ethylacetate is used in an amount of 2 to 6 times by volume with respect to the reaction solvent in the work-up procedure.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/KR 96/00250

A. CLASSIFICATION OF SUBJECT MATTER

IPC⁶: C 07 D 501/18, 501/04; A 61 K 31/545

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC⁶: C 07 D 501/18, 501/04

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

AT

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

DARC

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 95/35 020 A2 (ANTIBIOTICOS S.P.A.) 28 December 1995 (28.12.95), abstract.	1-19
A	Chemical Abstracts, Vol.114, No.7, 18 February 1991 (Columbus, Ohio, USA), page 656, column 1, abstract No.61761t, SAKANE K. et al.: "Studies on FK482 (Cefdinir). III. Synthesis and structure-activity relationships of 7B-[(Z)-2-aryl-2-hydroxyiminoacetamido]-3-vinyl-3-vinyl-3-cephem-4-carboxylic acid derivatives", & Yakagaku Zasshi 1990, 110(9), 658-64 (Japan).	1,9
A	Chemical Abstracts, Vol.114, No.15, 15 April 1991 (Columbus, Ohio, USA), page 734, column 1, abstract No.142931a, INAMOTO Y. et al.: "Studies on FK482 (Cefdinir). IV. Synthesis and structure-activity relationships of 7B-[(Z)-2-(2-aminothiazol-4-yl)-2-hydroxyiminoacetamido]-3-substituted cephalosporin derivatives", & Yakagaku Zasshi 1990, 110(12), 908-15 (Japan).	1,9

Further documents are listed in the continuation of Box C. See patent family annex.

- * Special categories of cited documents:
 - "A" document defining the general state of the art which is not considered to be of particular relevance
 - "E" earlier document but published on or after the international filing date
 - "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
 - "O" document referring to an oral disclosure, use, exhibition or other means
 - "P" document published prior to the international filing date but later than the priority date claimed
- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
17 April 1997 (17.04.97)	23 April 1997 (23.04.97)

Name and mailing address of the ISA/ AT AUSTRIAN PATENT OFFICE Kohlmarkt 8-10 A-1014 Vienna Facsimile No. 1/53424/535	Authorized officer Brus Telephone No. 1/5337058/32
---	--

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.

PCT/KR 96/00250

Im Recherchenbericht angeführtes Patentdokument Patent document cited in search report Document de brevet cité dans le rapport de recherche	Datum der Veröffentlichung Publication date Date de publication	Mitglied(er) der Patentfamilie Patent family member(s) Membre(s) de la famille de brevets	Datum der Veröffentlichung Publication date Date de publication
WO A2 9535020	26-12-95	CN A 113090P EP A1 720611 IT A0 95500624 IT A1 95500625 WO A2 9535020 IT A0 94501562	11-09-96 10-07-96 21-04-96 21-10-96 01-02-96 22-07-94

WO 95/35 020 A1

There are disclosed new compounds of formula (I), wherein R is: a hydrogen atom, a linear or branched C1-C4 alkyl group, unsubstituted or substituted by at least a phenyl group or at least a hydrogen atom, a benzyl group substituted by at least a linear or branched C1-C4 alkyl or alkoxy group or a nitro group, a silyl substituted by at least a linear or branched, unsubstituted or substituted C1-C4 alkyl group.

Chemical Abstracts 61761t

The synthesis, antibacterial activity and oral absorption of the 7β -[(Z)-2-aryl-2-hydroxy-iminoacetamidol]-3-vinylcephalosporins are described. All of these compounds exhibited excellent activity against *Staphylococcus aureus*. Against Gram-negative bacteria FK482 exhibited better activity than the first called compound. The relationship between the oral absorption rates and the lipophilicity of these cephalosporins was discussed.

Chemical Abstracts 142931a

The synthesis of 7β -[(Z)-2-(aminothiazol-4-yl)-2-hydroxyiminoacetamido]-cephalosporins modified at the C-3 position of a cepham nucleus and the effect of the C-3 substituents on the antibacterial activity and oral absorbability are discussed. The cephems having a C-3 substituent such as 1-propenyl, ethylthio and vinylthio group as well as cefdinir exhibited excellent antibacterial activities against both Gram-positive and Gram-negative bacteria. However, those compounds showed poor absorption rate after oral administration in rats. It is concluded that the vinyl moiety at the 3-position is necessary to display fairly oral absorptivity in a series of such cephems.

THIS PAGE BLANK (USPTO)